Aggregator compounds confound amyloid fibrillization assay

摘要

The highly sensitive and artificial biochemical assays that enable high-throughput screening are vulnerable to artifact-generating compounds that occur in drug screening collections. An investigation of known aggregator compounds and amyloid fibrillization inhibitors suggests that such inhibitors operate via a nonspecific mechanism in a well-used assay of amyloid fibrillization.